
HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034) | ...
The future of the HER2-low cancer treatment market is poised for significant transformation, driven by the approval of ENHERTU and the advancement of other innovative antibody-drug conjugates (ADCs) like DATROWAY, TRODELVY, ifinatamab deruxtecan, BB-1701, …